Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,187 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial.
Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R; BEAUTIFUL Investigators. Fox K, et al. Among authors: steg pg. Eur Heart J. 2009 Oct;30(19):2337-45. doi: 10.1093/eurheartj/ehp358. Epub 2009 Aug 31. Eur Heart J. 2009. PMID: 19720635 Clinical Trial.
Combined Abciximab REteplase Stent Study in acute myocardial infarction (CARESS in AMI).
Di Mario C, Bolognese L, Maillard L, Dudek D, Gambarati G, Manari A, Guiducci V, Patrizi G, Rusconi LC, Piovaccari G, Hibon AR, Belpomme V, Indolfi C, Olivari Z, Steffenino G, Zmudka K, Airoldi F, Panzarasa R, Flather M, Steg PG. Di Mario C, et al. Among authors: steg pg. Am Heart J. 2004 Sep;148(3):378-85. doi: 10.1016/j.ahj.2004.03.038. Am Heart J. 2004. PMID: 15389222 Clinical Trial.
Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
Fox K, Ferrari R, Tendera M, Steg PG, Ford I; BEAUTIFUL Steering Committee. Fox K, et al. Among authors: steg pg. Am Heart J. 2006 Nov;152(5):860-6. doi: 10.1016/j.ahj.2006.01.013. Am Heart J. 2006. PMID: 17070146
Resting heart rate in cardiovascular disease.
Fox K, Borer JS, Camm AJ, Danchin N, Ferrari R, Lopez Sendon JL, Steg PG, Tardif JC, Tavazzi L, Tendera M; Heart Rate Working Group. Fox K, et al. Among authors: steg pg. J Am Coll Cardiol. 2007 Aug 28;50(9):823-30. doi: 10.1016/j.jacc.2007.04.079. Epub 2007 Aug 13. J Am Coll Cardiol. 2007. PMID: 17719466 Free article. Review.
Modifiable risk factors control and its relationship with 1 year outcomes after coronary artery bypass surgery: insights from the REACH registry.
Mehta RH, Bhatt DL, Steg PG, Goto S, Hirsch AT, Liau CS, Röther J, Wilson PW, Richard AJ, Eagle KA, Ohman EM; REACH Registry Investigators. Mehta RH, et al. Among authors: steg pg. Eur Heart J. 2008 Dec;29(24):3052-60. doi: 10.1093/eurheartj/ehn478. Epub 2008 Nov 7. Eur Heart J. 2008. PMID: 18996953 Free PMC article.
1,187 results